As the regulatory landscape around the governance of artificial intelligence, health data reuse and innovation continues to evolve, our research and innovation community find themselves navigating a transition from one set of known governance expectations to additional challenges.
Researchers from i~HD have recently published a triad of publications on the identification of active substances and dose forms in medicinal products.
Researchers from i~HD have recently published a triad of publications on the identification of active substances and dose forms in medicinal products.
MedTech companies can offer benefits to multiple stakeholders within the healthcare ecosystem. Especially when it comes to the use and reuse of health data. But to unlock all this potential, we need to ensure that the data is of high quality.
2021 has been a breath-taking year in which we have grown our team, welcomed new members, developed new services, started new projects, and run round tables and workshops. You can discover more details on these exciting developments in our annual report 2021.
i~HD will deliver a keynote presentation titled “Harnessing the Power of Real-World Data (RWD) for Clinical Research: European Initiatives”.
i~HD’s Dipak Kalra will deliver a keynote presentation titled “Harnessing the Power of Real-World Data (RWD) for Clinical Research: European Initiatives”.
A study based on anonymised health records from over 8 million people in the UK and Spain found no evidence of a link between COVID-19 vaccines and 3 neurological disorders. However, there was an increased risk of these disorders, seen in people who had a COVID-19 infection.
Six experts from different fields gathered for the European Health Summit Taskforce Public Debate to discuss AI in Healthcare.  i~HD President Prof. Dipak Kalra moderated this debate.
Four members of the i~HD team will be presenting during the 8th European Conference on Health Law.
i~HD